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While there are no established pretreatment predictive and prognostic factors in patients 
with stage IIIA/pN2 non-small cell lung cancer (NSCLC) indicating a benefit to surgery 
as a part of trimodality approach, little is known about treatment-related predictive and 
prognostic factors in this setting. A literature search was conducted to identify possible 
treatment-related predictive and prognostic factors for patients for whom trimodality 
approach was reported on. Overall survival was the primary endpoint of this study. 
Of 30 identified studies, there were two phase II studies, 5 “prospective” studies, and 
23 retrospective studies. No study was found which specifically looked at treatment- 
related predictive factors of improved outcomes in trimodality treatment. Of potential 
treatment-related prognostic factors, the least frequently analyzed factors among 30 
available studies were overall pathologic stage after preoperative treatment and UICC 
downstaging. Evaluation of treatment response before surgery and by pathologic tumor 
stage after induction therapy were analyzed in slightly more than 40% of studies and 
found not to influence survival. More frequently studied factors—resection status, 
degree of tumor regression, and pathologic nodal stage after induction therapy as well 
as the most frequently studied factor, the treatment (in almost 75% studies)—showed 
no discernible impact on survival, due to conflicting results. Currently, it is impossible to 
identify any treatment-related predictive or prognostic factors for selecting surgery in the 
treatment of patients with stage IIIA/pN2 NSCLC.
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iNTRODUCTiON
Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease presentation based on 
the range of patient and tumor characteristics included under its heading. Concurrent radio-
chemotherapy (RT-CHT) is the standard treatment approach for locally advanced stage III NSCLC 
(1–3). In patients with stage IIIA/pN2 disease, thoracic oncologists have explored various means of 
optimizing treatment approach. Treatment regimens consisting of surgery alone or in combination 
with adjuvant CHT- and/or RT have been historically among the most common approaches used, 
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with recent decades showing a trend for induction regimens 
followed by surgery. The latter have included induction CHT 
followed by surgery (4–7), and, in more recent years, induction 
RT-CHT followed by surgery (8–34). When tested in prospective 
randomized phase III studies, preoperative RT (PORT)-CHT 
(with or without preceding CHT) followed by surgery brought no 
improvement in overall survival (OS) or local control compared 
to definitive concurrent RT-CHT, and was associated also with an 
increase in treatment-related mortality (8, 10, 35, 36).
Notwithstanding this high level evidence, there exists reluc-
tance among many clinicians to rule out the use of surgery in 
stage III NSCLC. For example, in an unplanned subgroup analysis 
of the Intergroup 0139 trial (10), it appeared that patients who 
underwent lobectomy as a component of their trimodality 
regimen had improved OS compared to the patients who received 
definitive RT-CHT. Given the controversial role of surgery in the 
management of this disease, looking at patient, tumor, and treat-
ment variables from the range of studies in stage III NSCLC might 
then provide guidance as to which might favor including surgery 
as part of patient care.
Recently, a survey of the literature tested the role of surgical 
treatment in the care of stage III NSCLC patients (37). Important 
finding was that there were no pretreatment factors that identi-
fied any patient subgroup whose outcomes were improved by 
the addition of surgery. In addition, the majority of studies did 
not consistently evaluate prognostic factors that may have had 
an impact on treatment outcomes, but when done, none of the 
three most frequently analyzed factors (age, gender, histology) 
was found to clearly influence survival. From this, it was con-
cluded that there were no specific pretreatment factors which 
favorably selected patients for surgery as a part of trimodality 
program (over definitive concurrent RT-CHT).
While little is known about treatment-related factors, the aim 
of the present study is to identify if potential treatment-related 
(i.e., after completion of induction therapy) predictive and prog-
nostic factors exist that can help optimize the selection of patients 
for a trimodality approach for their stage IIIA/pN2 disease.
MATeRiALS AND MeTHODS
References were identified through a literature search using 
PubMed, Google Scholar, EMBASE the terms “non-small cell 
lung cancer,” “surgery,” “radiotherapy,” “chemotherapy,” and 
“Stage IIIA” for the interval from 1990 until October 2017 as well 
as through searches of the references of the identified articles as 
well as of the authors’ own files. The year 1990 was selected as 
the starting point for the survey to mark for the contemporary 
era of RT delivery. Findings were restricted to English language 
publications in which potential treatment-related predictive 
and prognostic factors in the trimodality setting of concurrent 
RT-CHT (with or without preceding CHT) followed by surgery 
primarily focusing on Stage IIIA/pN2 (Stage III) were investi-
gated. We principally sought out the highest level of evidence 
(from prospective randomized phase III trials). Upon finding 
none, the search was expanded to include prospective research 
(formal phase II or studies described only as “prospective”), 
and following that, all available retrospective studies using a 
trimodality approach meeting the criteria detailed above. Due 
to substantial heterogeneity in the sources, studies invariably 
included those with a mixture of patients (i.e., with both early 
and late stages NSCLC); they have also included patients treated 
with a variety of adjuvant therapies [e.g., PORT, or postoperative 
CHT (POCHT)]. Studies involving patients with superior sulcus/
Pancoast/thoracic inlet tumors were excluded from the search. 
No study was excluded based on the form of induction CHT 
(drugs, regimens, administration, number of cycles), the form 
of RT (total doses delivered, once- or twice-daily fractionation, 
split- or continuous course), the type of surgery (pneumonec-
tomy, bilobectomy, lobectomy) or adjuvant therapies (PORT or 
POCHT) employed. Any potential predictive or prognostic factor 
that was considered in a given study was included in the analysis.
Using Clark methodology (38, 39) predictive factor was defined 
as the one which defines the effect of treatment on the tumor, 
while a prognostic factor was defined as one which defines the 
independent impact of a given variable on the patient outcome. 
If one attempts to meaningfully use such predictors to guide the 
selection patients for trimodality approach, evaluation of clini-
cally relevant endpoints (e.g., survival) should be used while the 
independent influence of these factors on a relevant endpoint 
(e.g., survival) distinguished from their ability to predict a dif-
ferential clinical benefit from the specific treatment (e.g., PORT-
CHT followed by surgery) (38, 39).
The purpose of this analysis is to determine if the survival 
benefit of patients treated surgically relative to patients treated 
with exclusive concurrent RT-CHT differs by any treatment-
related characteristic, and thus establish the significance of a 
potential predictor. To establish the significance of such potential 
prognostic factors, it would be necessary to demonstrate its inde-
pendent influence on treatment outcome. The current analysis 
was, therefore, restricted to studies that have provided such data 
and excluded studies that either did not discuss these or those 
in which they were described in univariate analyses only. Also, 
when the study using both univariate and multivariate analysis 
(MVA) disclosed factors that were not shown to influence 
survival on univariate analysis (and, therefore, subsequently, 
not entered into a multivariate model), such study was excluded 
from consideration. Finally, we excluded from consideration all 
studies that used multivariate analyses for subgroups of patients 
that were a part of the whole cohort of patients entering the 
published study.
In both prospective and retrospective series, multivariate 
analyses are used to investigate (treatment-related) prognostic 
factors, while the detection of treatment-related predictive factors 
requires more stringent criteria (38, 39). For the latter, one must 
determine if the survival benefit of patients on the investigational 
arm relative to patients on the control arm differ by treatment 
characteristic status. As an example, when survival by treatment 
arm for patients with documented mediastinal downstaging is 
compared to that for patients without this finding, one may find 
that the relative treatment benefit is similar. Then, looking at the 
survival results for all combinations of treatments and in whom 
documented mediastinal downstaging or not is determined, and 
if tests for interaction between mediastinal downstaging and 
treatment is not statistically significant, one may conclude that 
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although mediastinal downstaging is a strong prognostic factor, 
it does not predict a differential survival benefit between the 
experimental treatment and the control treatment dependent on 
mediastinal downstaging.
Overall survival was the primary endpoint in this analysis and 
was provided in all identified studies. Loco-regional and distant 
metastasis-free survival as well as treatment-related toxicity, 
including serious adverse events, were not considered endpoints 
for this study, since they were absent in some of the identified 
studies. When presenting the study finding we used a qualitative 
approach (yes vs no) (Table 1). Tests of significance for a given 
study were not included in our summary table. Individual patient 
data was not sought for this analysis.
ReSULTS
Using Clark methodology (38, 39), we did not identify any 
study investigating treatment-related predictive factors for the 
potential superiority of surgical outcomes in patients with Stage 
IIIA (mostly pN2) NSCLC. A total of 30 studies which provided 
information on prognostic factors in trimodality studies using 
MVA (Cox proportional hazards model) were found for the 
interval of interest. Of these, there were two prospective phase 
II studies (16, 40), five prospective studies (11, 12, 18, 22, 41), 
and 23 retrospective studies (13–15, 20, 21, 23–32, 34, 42–48) 
(Table 1). Of these 30 studies, 17 were single arm studies, while 
the remaining 13 were two-arm studies. Of the latter, five studies 
compared concurrent RT-CHT vs a trimodality approach, one 
compared surgery alone with a trimodality approach, while the 
remaining seven studies compared induction CHT followed by 
surgery with induction RT-CHT followed by surgery. Of the total 
of 30 studies, 12 studies either allowed (in cases of high-risk fea-
tures) or mandated (irrespective of risk features) the use of vari-
ous forms of adjuvant or postoperative treatment. This included 
PORT alone, POCHT alone as well as postoperative RT-CHT. 
The total number of patients in these 30 studies was 3,397, of 
which 3,071 (90%) patients underwent surgical resection. Total 
of 14 studies included Stages IIIA and IIIB patients, three studies 
included patients with earlier (IB, II, and IIB) and/or higher (IV) 
stages. The 13 remaining studies defined staging through status 
of the nodes, of which the majority had N2 disease. All studies 
considered used OS as an endpoint.
A total of eight treatment-related variables were examined as 
potential prognosticators in these studies (Table  1). Of these, 
UICC downstaging and pathologic staging post-induction ther-
apy (ypStaging) were the least frequently analyzed (in 2 and 5 
out of 30 available studies, respectively) and, thus, cannot provide 
a measure of their influence on treatment outcome. Evaluation 
of treatment response before surgery (by clinical means) and 
pathologic tumor size after induction therapy (ypT) was looked 
at in slightly more than 40% of studies and found likely not to 
influence survival. Although done most frequently, investiga-
tions of the influence of treatment modalities, when given either 
alone or in various combinations, revealed no consistent result. 
In particular, there was an equal number of positive and negative 
studies investigating induction CHT vs induction RT-CHT, and 
which, between studies, showed either a positive or negative 
influence of the extent of surgery, in particular pneumonectomy 
(vs lesser operations). Of three clinically recognized important 
prognosticators, namely, surgical resection status (R0 vs R1 or R0 
vs R+), degree of tumor regression after induction treatment as 
well as pathologic nodal status after induction (ypN) (in which 
there was great variability in reporting) analyses again revealed 
inconclusive results for the majority of eligible 30 studies 
(Table 1).
DiSCUSSiON
The present study looked at treatment-related factors that could 
aid in optimizing patient selection in the setting of trimodality 
treatment approach for Stage IIIA (primarily pN2) NSCLC. 
Similar to a recent study on pretreatment predictive and prog-
nostic factors (37), we first noted inconsistent use of clinical 
definitions in this setting by clinicians. While we employed the 
definition of Clark (38, 39) to identify potential predictive factors, 
we found that that term was inaccurately used in most studies 
which then led to their incorrect inclusion in MVAs. In other 
words, MVAs reveal prognostic factors and not predictive ones.
Second, we found wide heterogeneity among studies with 
respect to diagnostic, staging, and treatment procedures, 
as well as different systems used to detect tumor response in 
surgical specimens. This led to significant inconsistencies in 
how potential treatment-related factors could be investigated. 
In particular, the majority of studies have used mediastinoscopy 
to prove pN2 while in some studies pathological mediastinal 
disease was found during surgery. It introduces potential bias in 
interpretation of the study results as patients with preoperatively 
confirmed N2 may have had worse prognosis than those with 
pN2 found at surgery and, possibly, could have different predic-
tive and prognostic factors in the trimodality setting of Stage 
IIIA NSCLC.
Mindful of these shortcomings, we were unable to identify any 
prospective randomized study which investigated predictive fac-
tors in the setting of trimodality therapy, or the group of retrospec-
tive studies which compared bi- and trimodality approach. Third, 
we found that potential treatment-related prognostic factors 
were not consistently evaluated. Factors, such as post-induction 
therapy staging (ypStaging) or UICC downstaging, were looked 
at in less than 20% of all eligible studies; while factors, such as the 
degree of tumor regression, status of surgical margins, evaluation 
of response before surgery, or post-induction tumor status (ypT), 
were evaluated slightly more than 40% of all available studies. 
This limited our ability to detect the potential influence of any 
of these factors on treatment outcome. The factor more often 
investigated, post-induction nodal status (ypN), presented the 
same difficulty. No firm conclusions could be drawn possibly 
because of inconsistent definitions used for this across studies: 
some investigators used different comparators, either focusing on 
mediastinal nodal clearance (i.e., ypN0-1 vs ypN2), or only on 
ypN0 vs ypN+ or simply testing for the independent influence of 
a variable ypN (yes vs no).
The variable use of adjuvant treatments further contributed 
to the difficulty in assessing post-induction factors: while the 
majority of studies did not involve their use, for those that did, 
TAbLe 1 | Treatment characteristics as potential prognosticators.
Reference Study Response  
before surgerya
Treatmenta  
(all possible variables)
Resection  
status
Degree of tumor 
regressiona
yp Stage ypT a ypN UiCC  
downstaging
Adelstein et al. (16) Prospective 
phase II
No—clinical Not evaluated Not evaluated Yes—pCR or  
pPR vs pNR
Not evaluated Not evaluated No—pN0 Not evaluated
Park et al. (40) Not evaluated No—R0 Not evaluated Yes—pN0-1
Choi et al. (11) Prospective No Yes (CR—R0) Yes—yp0 vs  
ypN1-2
Thomas et al. (12) Not evaluated Yes (R0 vs R+) Yes (>90 vs <90%) Not evaluated
Pezzetta et al. (22) No—induction CHT vs  
induction RT-CHT
Not evaluated Not evaluated Yes—ypN0 vs  
ypN1-2
Kim et al. (18) Not evaluated No—
Necrosisproportion; 
no—viable tumor 
proportion
No—pT0-pT4
Isobe et al. (41) No (clinical  
response)
Not evaluated No (resectability) Yes No Not evaluated No (pNo vs pN2-3)
Cyjon et al (20). Retrospective No No—number of 
CHT cycles
Yes—CR (R0) Not evaluated Not evaluated Not evaluated Not evaluated
Sawabata et al. (21) Not evaluated Not evaluated No—R0 vs R1 No—pT0-pT4 Yes -pN0-pN2 (single) 
vs pN2 (multiple)-N3
Takeda et al. (13) No No Not evaluated Not evaluated Not evaluated
Caglar et al. (14) Not evaluated Yes—surgery; no—CHT
Steger et al. (15) No—Extent of surgery 
(pneumonectomy) 
No—Regression 
score >IIb (<10% 
viable tumor tissue)
No—ypT 
downstaging
No Yes—ypUICC
Li (23) No (CR-PR vs SD-PD) No—RT; no—POCHT Yes—R0 vs R+ Yes—pCR or  
pPR vs pNR
Not evaluated Yes—ypN0-1 vs 
ypN2 (mediastinal 
downstaging)
Not evaluated
Li J (24) Not evaluated Not evaluated Not evaluated
Weder et al (25) No No—type of surgery  
(pneumonectomy)
Not evaluated No—ypStage No—ypT No—ypN
Meacci et al. (26) No—extent of surgery Yes (R0 vs R1) Not evaluated Not evaluated not evaluated
Kim et al (27) Not evaluated Yes—extent of surgery  
(worse for pneumonectomy)
Not evaluated No—yp0 
(CR) vs yp 
(I + II + III)
No—ypN0 vs  
ypN1-2
Shumway et al. (28) No—RT, No—CHT;  
no—extent of surgery
Not evaluated Not evaluated
Shintani et al. (29) No Not evaluated Yes—pN0-1 vs pN2
(mediastinal 
downstaging)
(Continued )
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Reference Study Response  
before surgerya
Treatmenta  
(all possible variables)
Resection  
status
Degree of tumor 
regressiona
yp Stage ypT a ypN UiCC  
downstaging
Steger et al. (30) Not evaluated No—
ypT0N0M0
No No Yes—ypUICC
Gómez-Caro et al. 
(31)
Yes (trimodality superior  
to surgery only)
No—pStage 
(I–II/III–IV)
No—yp1-2 vs 
ypT3-4
Not evaluated Not evaluated
Toyooka et al. (32) Yes—(induction CRT  
superior to induction CT);  
no—extent of surgery
No—pCR (+ vs -) Not evaluated No—ypT Yes—yp0-1 vs ypN2
(mediastinal 
downstaging)
Askoxylakis et al. (42) No—induction CHT;  
no—non-CDDP
Not evaluated Not evaluated Not evaluated
Lee et al. (43) Yes—type of CHT; yes— 
type of surgery (worse for 
pneumonectomy);  
yes—PORT; POCHT
No—resection 
margin (negative 
vs close/positive)
No—ypT0 vs 
ypT1-4
Yes—ypN0 vs ypN+
Renaud et al. (45) No (pN downstaging 
after induction 
treatment)
No (type of surgery) Not evaluated No Yes
Lim et al (34) No—clinical response; 
no— 
tumor size on post-
induction treatment; 
yes—% change of 
target lesions on post-
induction treatment
No—type of operation;  
no—adjuvant treatment
Not evaluated No—total tumor 
size on surgical 
specimen; yes—
viable tumor size on 
surgical specimen
No—pN0, pN1, pN2
Shien et al. (46) No (radiological 
response)
No (type of surgery) No (pCR) No (pT3 vs pTN0-2) No (pN0-1 vs pN2-3)
Darling et al. (47) Not evaluated Yes (surgery) Not evaluated Not evaluated Not evaluated
Kim et al. (44) Not evaluated Yes—type of surgery  
(worse for pneumonectomy)
Yes—close or 
positive margins
Yes—advanced pT Yes—persistent N2
Yang et al (48) Yes (surgery) Not evaluated Not evaluated Not evaluated
Summary Yes/no/not 
evaluated
1/13/18 10/19/10 8/4/18 5/5/21 0/5/25 2/11/18 11/8/11 2/0/28
INTERPRET Unknown;  
possibly not
Possibly not Unknown Unknown Unknown Unknown; possibly 
not
Unknown Unknown
aMore than one finding per study (the same for both RT, chemo, surgery).
n.e., not evaluated; UICC, International Union Against Cancer; yp, pathological evaluation done after induction treatment (on operative specimen); pCR, pathological complete response; pPR, pathological partial response; pNR, 
pathological no response; R0, negative surgical margins; R1, microscopically positive resected tumor margins; R+, positive resected tumor margins; RT, radiotherapy; CHT, chemotherapy; PORT, postoperative RT; POCHT, 
postoperative CHT.
TAbLe 1 | Continued
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major factors in predicting poor surgical outcomes, such that 
R0 is considered superior to any R+ status, we observed no such 
consistent association between studies and could not establish 
the importance of this factor.
Radiographic (clinical) response evaluations after induction 
therapy had a limited role in our analysis. In that regard, it is gen-
erally accepted that these are unreliable measures of the benefits 
of therapy as they are easily confounded. Contemporary studies 
that use novel approaches (e.g., PET-CT based response evalua-
tions) and which could help in identifying such factors remain 
to be published. Future studies are required that incorporate this 
form of imaging which is then correlated with surgical/pathologi-
cal findings.
The form of the surgical approach (all approaches consid-
ered) was also shown not to influence survival. The extent of 
surgery (pneumonectomy vs lesser operations) may simply be 
a surrogate for the bulk of the disease, so that the larger tumor 
burden by its nature carries the worse prognosis independent 
of surgical approach. A consistent definition of tumor burden 
prior to surgical intervention would clarify the impact of surgery 
in future studies where pneumonectomy is allowed since the 
decision of pneumonectomy vs lobectomy is also dependent on 
the location of the primary and nodal disease. This seems to be 
very important aspects, especially after Intergroup 0139 study 
results became available (10) showing worse survival for patients 
treated with trimodality approach using pneumonectomy vs 
lobectomy. Likewise, consistent stratification factors and trial 
eligibility criteria across studies and between research consortia 
would help better interpret conflicting results such as those 
in the histological domain which in EORTC study (8) favored 
squamous cell carcinoma while in Nordic study (36) favored 
adenocarcinoma.
The findings of the current study highlight our inability to use 
published study-derived treatment-related factors as either pre-
dictors or prognosticators to evaluate their impact in this clinical 
setting and to aid in the decision-making process regarding 
the appropriateness of surgery in stage III NSCLC. They follow 
our previous effort which focused on the pretreatment patient 
and tumor predictive and/or prognostic factors in this setting 
(37). Similar to it (37), although with slightly different number 
of included studies, the current one also could not identify 
such factors. This brings significant uncertainty in the process 
of decision-making before and after induction treatment was 
administered. It also reemphasizes the need for a more universal 
approach to defining and exploring treatment-related predictive 
and prognostic factor analysis in future studies, which needs to 
be coordinated across groups and countries. Possible avenues 
for clinical research in this setting would include more PRCTs 
with statistical analysis including predictive factor analysis being 
mandatory. In addition, a number of studies identified treatment-
related factors that need to be further tested for its predictive and/
or prognostic influence in this setting. This could be done as a 
preliminary step in the research scenario and, if repeatedly posi-
tive, across of various groups and institutions as to identify likely 
candidates for entering more patient and/or treatment-shaped 
trial milieu.
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